Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Fluticasone Furoate Ellipta
Generic Name
Fluticasone Furoate
Active Ingredient
Fluticasone FuroateCategory
Other
Variants
3
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Fluticasone Furoate Ellipta, you must consult a qualified healthcare professional.
Detailed information about Fluticasone Furoate Ellipta
Fluticasone furoate is a high-potency synthetic corticosteroid used to manage inflammatory conditions such as allergic rhinitis, asthma, and COPD. It works by reducing airway and nasal inflammation through glucocorticoid receptor activation.
Dosage of fluticasone furoate varies significantly based on the condition being treated and the specific product formulation.
No dosage adjustment is required for patients with renal (kidney) impairment, as less than 1% of the drug is excreted via the kidneys.
Fluticasone furoate is extensively metabolized by the liver. Patients with moderate to severe hepatic (liver) impairment should be monitored closely for signs of systemic corticosteroid effects (such as weight gain or high blood pressure). In some cases, a dose adjustment may be considered by the physician, particularly with combination products, as systemic exposure can increase significantly when liver function is compromised.
No overall differences in safety or effectiveness have been observed between elderly patients and younger patients. No specific dosage adjustments are typically required based on age alone, though clinicians should be mindful of co-existing conditions and other medications.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one. Consistency is key for the effectiveness of fluticasone furoate.
An acute overdose of fluticasone furoate is unlikely to be life-threatening given the low systemic absorption. Chronic overdose (using more than prescribed over a long period) can lead to symptoms of hypercorticism, such as Cushing's syndrome (weight gain in the trunk, moon face, thinning skin). If you suspect a significant overdose, contact a poison control center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. If your symptoms do not improve after several days of treatment, consult your doctor.
Side effects of fluticasone furoate are generally localized to the site of administration. For the nasal spray, the most common side effect is epistaxis (nosebleeds). This occurs because the steroid can thin the nasal mucosa (lining) over time. Patients may notice small amounts of blood when blowing their nose or occasional spotting. Another common side effect is headache, which is usually mild and transient.
For the inhaled version (Arnuity Ellipta), the most common side effect is nasopharyngitis (sore throat and runny nose), occurring in more than 10% of clinical trial participants. This often feels like the beginning of a common cold. Upper respiratory tract infections are also frequently reported.
Fluticasone furoate is a maintenance medication and must be used regularly to be effective. It should not be used as a 'rescue' medication for sudden breathing problems. Patients must always have a fast-acting rescue inhaler (like albuterol) available for acute asthma attacks. If your symptoms do not improve or if they worsen despite regular use, you must seek medical advice promptly.
No FDA black box warnings for Fluticasone Furoate as a single-entity product.
There are no absolute drug-drug contraindications where the combination is strictly forbidden for every patient; however, use with Ritonavir (Norvir) is generally avoided unless the benefit outweighs the risk. Ritonavir is a potent inhibitor of the CYP3A4 enzyme. Co-administration can lead to a massive increase in systemic fluticasone levels (up to several hundred-fold), resulting in Cushing’s syndrome and secondary adrenal insufficiency.
Fluticasone furoate must NEVER be used in the following circumstances:
Fluticasone furoate is classified under the older FDA Pregnancy Category C logic. There are no adequate and well-controlled studies of fluticasone furoate in pregnant women. Animal studies have shown that systemic exposure to corticosteroids can cause malformations (such as cleft palate and fetal growth retardation), but the systemic exposure from nasal or inhaled fluticasone furoate at recommended doses is extremely low.
Clinical guidelines generally suggest that maintaining control of asthma is vital during pregnancy to prevent maternal and fetal complications from hypoxia (low oxygen). Therefore, fluticasone furoate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers receiving substantial doses of corticosteroids during pregnancy should be monitored for signs of hypoadrenalism.
It is not known whether fluticasone furoate is excreted in human breast milk. However, other corticosteroids are known to be excreted in small amounts. Because the systemic bioavailability of fluticasone furoate after nasal or inhaled administration is less than 1%, the levels in breast milk are expected to be negligibly low. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for the drug. As a precaution, monitor the nursing infant for any signs of systemic effects.
Fluticasone furoate is a synthetic glucocorticoid with high affinity for the human glucocorticoid receptor (GR). Its molecular mechanism involves the modulation of gene transcription. Upon binding to the GR, the complex translocates to the nucleus and binds to glucocorticoid response elements (GREs). This results in the induction of anti-inflammatory proteins (like lipocortin-1) and the inhibition of pro-inflammatory transcription factors such as NF-kappaB and AP-1. This leads to a decrease in the production of various inflammatory mediators, including IL-4, IL-5, and various chemokines, effectively dampening the allergic and asthmatic inflammatory response.
The pharmacodynamics of fluticasone furoate are characterized by a slow onset but long duration of action. In patients with allergic rhinitis, some improvement may be seen within 8-24 hours, but the full effect often takes several days of consistent use. In asthma, lung function improvements typically occur within 1-2 weeks of starting therapy. Because of its high receptor affinity and slow dissociation from the receptor, it is suitable for once-daily dosing.
| Parameter | Value |
Common questions about Fluticasone Furoate Ellipta
Fluticasone furoate is a potent corticosteroid medication used primarily to manage chronic inflammatory conditions of the respiratory system. In its nasal spray form, it is FDA-approved to treat the symptoms of seasonal and year-round allergies, such as nasal congestion, sneezing, and a runny nose. When used as an inhaler, it is indicated for the long-term maintenance treatment of asthma in adults and children aged 5 and older. It is also used in combination with other drugs to treat Chronic Obstructive Pulmonary Disease (COPD). It works by reducing inflammation in the airways or nasal passages, but it is not a rescue medication for acute attacks.
The most common side effects depend on how the medication is administered. For the nasal spray, patients frequently report nosebleeds (epistaxis), nasal irritation, and headaches. For the inhaled powder used for asthma, common side effects include sore throat (nasopharyngitis), upper respiratory tract infections, and a cough. Some patients may also develop oral thrush, which is a fungal infection in the mouth, if they do not rinse after using the inhaler. Most of these side effects are mild, but you should report any persistent or worsening symptoms to your healthcare provider.
There is no known direct interaction between alcohol and fluticasone furoate that would make it dangerous to consume in moderation. However, it is important to remember that alcohol can sometimes worsen the symptoms of allergies or asthma in certain individuals. Furthermore, heavy alcohol use can weaken the immune system, potentially complicating the management of respiratory infections. Since fluticasone furoate is a steroid that can slightly affect the immune response, maintaining a healthy lifestyle is beneficial. Always consult your doctor about your alcohol consumption habits while on maintenance medication.
Fluticasone furoate should be used during pregnancy only if the potential benefit to the mother outweighs the potential risk to the developing fetus. While animal studies have shown some risks with high systemic doses of steroids, the amount of fluticasone furoate that enters the bloodstream from a nasal spray or inhaler is extremely low. Controlling asthma is critical during pregnancy, as poorly controlled asthma can lead to low oxygen levels for the baby. Most doctors consider the risk of uncontrolled asthma to be greater than the risk of using inhaled steroids. You must have a detailed discussion with your obstetrician or healthcare provider to create a safe treatment plan.
Fluticasone furoate is not an immediate-acting medication and requires consistent use to reach its full effect. For allergic rhinitis, some patients may notice a slight improvement within 8 to 24 hours, but it typically takes several days of daily use to achieve maximum relief. For asthma, it may take 1 to 2 weeks of regular once-daily inhalation before a significant improvement in lung function is measured. Because it works by reducing underlying inflammation rather than just relaxing muscles, patience is required. Do not stop taking the medication if you don't feel better immediately; continue as prescribed by your doctor.
You should not stop taking fluticasone furoate suddenly without first consulting your healthcare provider, particularly if you are using it to manage asthma. Discontinuing the medication can cause your asthma or allergy symptoms to return or worsen quickly. If you have been using high doses or have recently transitioned from oral steroids, stopping abruptly could also lead to symptoms of adrenal insufficiency. If a change in treatment is necessary, your doctor will usually advise a gradual reduction in dose. Always follow your medical professional's guidance regarding the duration and cessation of therapy.
If you miss a dose of fluticasone furoate, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, you should skip the missed dose and simply take your next dose at the regular time. You should never take two doses at once or use extra medication to make up for a missed dose. Since this medication is designed for once-daily use, missing a single dose is unlikely to cause a major problem, but consistency is vital for long-term control. Setting a daily reminder can help you stay on track with your treatment schedule.
Weight gain is a common side effect of oral steroid tablets (like prednisone), but it is very rare with inhaled or nasal fluticasone furoate. Because the drug is applied locally to the nose or lungs and very little reaches the rest of the body, systemic side effects like significant weight gain or 'moon face' are unlikely at recommended doses. If a patient uses much higher doses than prescribed for a long period, some systemic absorption could occur, potentially leading to metabolic changes. If you notice unusual weight gain or swelling while using this medication, you should discuss it with your doctor to rule out other causes. Most patients do not experience weight changes with this drug.
Fluticasone furoate can be taken with many other medications, but there are some important exceptions you must be aware of. Specifically, drugs that inhibit the CYP3A4 enzyme, such as ritonavir (used for HIV) or ketoconazole (an antifungal), can significantly increase the levels of fluticasone in your body. This increase can lead to serious steroid-related side effects. It is also important to tell your doctor if you are using other forms of steroids, such as creams, injections, or tablets. Always provide your healthcare provider and pharmacist with a complete list of all prescription and over-the-counter medications you are currently taking.
Yes, fluticasone furoate is available as a generic medication, particularly in its nasal spray formulation. Generic versions of the nasal spray (equivalent to Flonase Sensimist or Veramyst) are widely available over-the-counter and by prescription. However, some of the specialized inhalation devices used for asthma and COPD, such as the Ellipta inhaler, may still be under patent protection in certain regions or may only be available as branded products. Generic medications contain the same active ingredient and meet the same FDA standards for safety and effectiveness as the brand-name versions. Check with your pharmacist to see if a lower-cost generic option is available for your specific prescription.
Other drugs with the same active ingredient (Fluticasone Furoate)
While fluticasone furoate is generally safe, serious reactions can occur.
> Warning: Stop taking Fluticasone Furoate and call your doctor immediately if you experience any of these:
Prolonged use of fluticasone furoate, especially at high doses, can lead to systemic corticosteroid effects, although the risk is lower than with oral prednisone. These include:
There are currently no FDA black box warnings for fluticasone furoate as a standalone ingredient. However, when fluticasone furoate is used in combination with long-acting beta-agonists (LABAs), there were previously warnings regarding asthma-related death. Following large safety trials, the FDA removed the Black Box Warning for LABA/ICS combinations in 2017, concluding that they do not significantly increase the risk of serious asthma-related events compared to ICS alone.
Report any unusual symptoms to your healthcare provider. Monitoring of growth in children and eye exams for adults on long-term therapy is recommended.
Healthcare providers may require the following monitoring during long-term therapy:
Fluticasone furoate is not known to cause sedation or impair cognitive function. It is generally considered safe to drive or operate machinery while using this medication.
There is no direct pharmacological interaction between alcohol and fluticasone furoate. However, excessive alcohol consumption can weaken the immune system and may worsen the underlying respiratory or allergic conditions being treated.
Do not stop taking fluticasone furoate abruptly without consulting your doctor, especially if you are using it for asthma. Sudden discontinuation can lead to a return of symptoms or, in those transitioning from oral steroids, signs of steroid withdrawal. If the medication needs to be stopped, your doctor will provide a tapering schedule if necessary.
> Important: Discuss all your medical conditions with your healthcare provider before starting Fluticasone Furoate, especially if you have a history of liver disease, weak bones, or eye problems.
Fluticasone furoate does not typically interfere with standard blood chemistry or hematology tests. However, it can affect tests designed to measure adrenal function:
For each major interaction, the mechanism usually involves the Cytochrome P450 3A4 enzyme. Inhibitors stop the liver from breaking down the drug, leading to toxicity (Cushing's symptoms). Inducers speed up the breakdown, potentially reducing the duration of the drug's effect.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter nasal sprays or skin creams.
In these conditions, the healthcare provider will perform a careful risk-benefit analysis:
While cross-sensitivity among different corticosteroids is not universal, patients who have had a severe allergic reaction to other glucocorticoids (like fluticasone propionate, mometasone, or budesonide) should be monitored closely when starting fluticasone furoate, as they may share similar chemical structures that the immune system recognizes.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of infections or recent surgeries, before prescribing Fluticasone Furoate.
Clinical trials included a sufficient number of patients aged 65 and over to determine that they respond similarly to younger patients. No dosage adjustment is typically required. However, elderly patients may be at higher risk for decreased bone mineral density and cataracts, so these factors should be monitored. Clinicians should also consider the higher likelihood of polypharmacy (taking multiple drugs) and the potential for CYP3A4 interactions in this population.
As the drug is not significantly cleared by the kidneys, renal impairment does not affect the pharmacokinetics of fluticasone furoate. No dose adjustments are needed for patients with kidney disease or those on dialysis.
Fluticasone furoate undergoes extensive hepatic metabolism via CYP3A4. In patients with moderate to severe hepatic impairment (Child-Pugh Class B or C), systemic exposure (AUC) can increase by up to 3-fold. This increase in blood levels may lead to higher risks of HPA axis suppression. Use with caution in patients with significant liver disease and monitor for signs of systemic steroid excess.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or nursing.
|---|---|
| Bioavailability | <1.39% (Inhaled/Nasal) |
| Protein Binding | >99% (Primarily Albumin) |
| Half-life | ~15.1 hours |
| Tmax | 0.5 to 1 hour (post-inhalation) |
| Metabolism | Hepatic (CYP3A4) |
| Excretion | Fecal (>90%), Renal (<1%) |
Fluticasone furoate is classified as a Corticosteroid (specifically a Glucocorticoid). Within the respiratory therapeutic area, it is categorized as an Inhaled Corticosteroid (ICS) or an Intranasal Corticosteroid (INS). It is related to other medications in this class such as fluticasone propionate, mometasone furoate, budesonide, and ciclesonide.